medigraphic.com

2008, Number 3

<< Back Next >>

Cir Cir 2008; 76 (3)

Serum levels of Apo-AI and Apo-B as markers of synthetic graft stenosis after bypass for peripheral artery disease

Guzmán-Lepe S, Anaya-Prado R

Language: Spanish
References: 44
Page: 225-233
PDF size: 84.29 Kb.


ABSTRACT

Background: Hiperlipidemias are the main risk factors for atherosclerosis and cardiovascular disease. Nevertheless, the protein fractions of these lipids such as apolipoprotein B (Apo-B) can lead to arterial obstruction. In this study we investigated levels of apolipoproteins AI and B in patients with chronic occlusive peripheral arterial disease (PAD) of the lower extremities and their association with either patency or stenosis of synthetic grafts.
Methods: This chohort study included 24 patients with chronic occlusive PAD who underwent infrainguinal revascularization with PTFE synthetic graft. Patients were divided into two groups according to their exposure or not to Apo-B, thus integrating two cohorts: the unexposed group (group 1, normal levels of Apo-B) and the exposed group (group 2, high levels of Apo-B). Variables investigated at 3, 6 and 12 months included arm/ankle index (AAI) and its association with levels of Apo-AI and Apo-B, and levels of cholesterol, triglycerides, and fibrinogen.
Results: The study comprised 67% men and 33% women. Average age was 65.2 ± 8.4 years. There was a correlation between AAI and high levels of Apo-B (p ‹0.001). Apo-AI levels were not significantly different between groups. Fibrinogen remained elevated in both groups with no statistical difference. Triglycerides demonstrated a significant difference between groups in basal measurements (p ‹0.05). Cholesterol remained normal in both groups without statistical difference.
Conclusions: This study demonstrates that patients exposed to high levels of Apo-B had synthetic graft failure (obstruction), as demonstrated by AAI ‹1.


REFERENCES

  1. 1. Aldons JL. Atherosclerosis. Nature 2000;407:233-241.

  2. 2. INEGI/SSA. Principales causas de mortalidad general, 2001 Nacional. Disponible en http://www.salud.gob.mx

  3. 3. Criqui MH, Fronek A, Barreto-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-515.

  4. 4. Hiatt WR, Hoan S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease: The San Luis Valley Diabetes Study. Circulation 1985;91:1472-1479.

  5. 5. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608-1620.

  6. 6. Grundy SM, Becker D, Clark LT, et al. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol Education in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.

  7. 7. Criqui MH, Golomb BA. Epidemiologic aspects of lipid abnormalities. Am J Med 1998;105:48S-57S.

  8. 8. Van der Steeg WA, Boekholdt SM, Stein EA, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007;146:640-648.

  9. 9. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high density lipoprotein and its apolipoproteins: an idea whose time for testing is coming. II. Circulation 2001;104:2376-2383.

  10. 10. Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med 1995;332:1491-1495.

  11. 11. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999;340:315-326.

  12. 12. Haimovici H. Historia de la cirugía vascular. En: Haimovici H, Ascer E, Hollier, eds. Cirugía Vascular. 4th ed. México, D.F.: Blackwell Scientific Publications;1996. pp. 3-17.

  13. 13. DeWeese JA, Leather R, Porter J. Practice guidelines: lower extremity revascularization. J Vasc Surg 1993;18:280-293.

  14. 14. Dormandy JA, Rutherford RB. Trans-Atlantic Inter-Society Consensus Working Group. Management of peripheral arterial disease (PAD). J Vasc Surg 2000;31:S5-S34.

  15. 15. Johnson WC, Lee KK. A comparative evaluation of polytetra-

  16. fluoroethylene, umbilical vein, and saphenous vein bypass grafts for femoral-popliteal above-knee revascularization: a prospective randomized Department of Veterans Affairs Cooperative Study. J Vasc Surg 2000;32:268-277.

  17. 16. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein B and AI distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES). Clin Chem 1997;43:2364-2378.

  18. 17. Asztalos BF, Schaefer EJ. High-density lipoprotein subpopulations in pathologic conditions. Am J Cardiol 2003;91:12-17.

  19. 18. Marsh JB, Welty FK, Lichtenstein AH, Lamon FS, Schaefer EJ. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 2002;162:227-247.

  20. 19. Young SG. Recent progress in understanding apolipoprotein B. Circulation 1990;82:1574-1594.

  21. 20. Spady DK. Reverse cholesterol transport and atherosclerosis regression. Circulation 1999;100:576-578.

  22. 21. Avogaro P, Bittolo Bon G, Cazzolato G, Quinci GB. Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet 1979;1:901-903.

  23. 22. Walldius G, Jungner I, Holme I, Aastveit A, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-2033.

  24. 23. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004;255:188-205.

  25. 24. Lamarche B, Moorjani S, Lupien P, Cantin B. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation 1996;94:273-278.

  26. 25. Peynet J, Beaudeux L, Woimant F, Flourie F. Apolipoprotein (a) size polymorphism in young adults with ischemic stroke. Atherosclerosis 1999;142:233-239.

  27. 26. Senti M, Nogues X, Pedro-Botet J, Rubies-Prat J, Vidal-Barranquer F. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation 1992;85:30-36.

  28. 27. Sniderman AD. How, when, and why to use apolipoprotein B in clinical practice. Am J Cardiol 2002;90:48-54.

  29. 28. Craig WY. Lipoprotein (a) levels in peripheral atherosclerotic disease. J Vasc Surg 1995;21:541.

  30. 29. Taylor LM, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg 1999;29:8-21.

  31. 30. Valentine RJ, Grayburn PA, Vega GL, Grundy SM. Lp (a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white men. Arch Intern Med 1994;154:801-806.

  32. 31. Kullo IJ, Ballantyne CM. Conditional risk factors for atherosclerosis. Mayo Clin Proc 2005;80:219-230.

  33. 32. Dionyssiou-Asteriou A, Papastamatiou M, Vatalas IA, Bastounis E. Serum apolipoprotein AI levels in atherosclerotic and diabetic patients. Eur J Vasc Endovasc Surg 2002;24:161-165.

  34. 33. Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease, and death. The Framingham Study. Arch Intern Med 1981;141:1128.

  35. 34. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002;22:1918-1923.

  36. 35. Lopez HG, Ramos LR, Ortiz LC, et al. Resultados del tratamiento quirúrgico de la revascularización infraguinal en pacientes con elevación de lipoproteína de baja densidad y fibrinógeno plasmático. Rev Mex Angiol 2002;30:43-47.

  37. 36. Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996;94:3026-3049.

  38. 37. Meijer WT, Hoes AW, Rutgers D, et al. Peripheral arterial disease in the elderly. The Rotterdam Study. Arterioscler Thromb Vasc Biol 1998;18:185-192.

  39. 38. Durrington P. HDL in risk prediction and its direct and indirect involvement in atherogenesis. Atherosclerosis 2002;(suppl):3-12.

  40. 39. Villar SJ, Server HR, Breto GM. Concentraciones séricas de las apolipoproteínas A-I y B en una población de la Comunidad Valencia: su utilidad para valorar el colesterol como factor de riesgo cardiovascular. Clin Invest Arteriosclerosis 2001;13:195-199.

  41. 40. Nissen SE, Tuzcu EM, Shoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein and coronary artery disease. N Engl J Med 2005;352:29-38.

  42. 41. Graham LM. Long-term alterations in large and small caliber arterial prostheses. In: Ernst CB, Stanley JC, eds. Current Therapy in Vascular Surgery. 4th ed. St. Louis: Mosby;2001. pp. 308-310.

  43. 42. Bandyk DF, Johnson BL, Gupta AK, Esses GE. Nature and management of duplex abnormalities encountered during infrainguinal vein bypass grafting. J Vasc Surg 1996;24:430-438.

  44. 43. Burger DH, Kappetein AP, Bockel JH, et al. A prospective randomized trial comparing vein with polytetrafluoroethylene in above-knee femoropopliteal bypass grafting. J Vasc Surg 2000;32:278-283.




2020     |     www.medigraphic.com